TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival |
Press Release2024, October 31 08:00 a.m. TME Pharma awarded €2.4 million German Federal grant to support NOX-A12 Phase 2 trial in brain cancer 2024, October 18 06:00 p.m. TME Pharma reports H1 2024 financial results and provides business and clinical update 2024, September 30 06:00 p.m. TME Pharma announces appointment of Alexandra Glucksmann to supervisory board |
EventsBIO-Europe
Dirk Eulberg, Ewelina Staniuk TIDES Europe
Aram Mangasarian, Stefan Vonhoff Latest Analyst Report |